Tech Company Financing Transactions
Genesis Therapeutics Funding Round
Genesis Therapeutics, based in San Francisco, received $200 million from Andreessen Horowitz, BlackRock and Fidelity Management & Research Company.
Transaction Overview
Company Name
Announced On
8/21/2023
Transaction Type
Venture Equity
Amount
$200,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to further invest in its AI platform, and expand its discovery pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
415 Grand Ave. 201
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Genesis Therapeutics is a biotechnology company that invents and deploys breakthrough AI techniques to discover and develop drugs both internally as well as in select partnerships. Genesis is unique in its groundbreaking deep learning technology, its synergy of machine learning with biophysical simulation and its pairing of AI with extensive biotech/pharma expertise.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Leonard Bell
Chief Executive Officer
Evan Feinberg
Chief Scientific Officer
Peppi Prasit
Vice President
Nick Stock
VP - Bus. Development
James Schaeffer
VP - Engineering
Benjamin Sklaroff
Browse more venture capital transactions:
Prev: 8/21/2023: Zanifu venture capital transaction
Next: 8/21/2023: Braintrust Tutors venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs